GlassScriptPhysician profile
Jasmeet Gill
NPI 1275702300
$2,770.52
in general payments reported to CMS, 2019-2025
25 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $468 · 2021: $257 · 2022: $215 · 2023: $329 · 2024: $254 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,013.69 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $415.02 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $287.84 | 2019-2023 | Spravato |
| Avanir Pharmaceuticals, INC. | $124.99 | 2019 | |
| Lilly USA, LLC | $116.89 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $102.28 | 2022-2025 | Trelegy Ellipta, Benlysta |
| Pfizer INC. | $99.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $71.91 | 2019-2025 | Airsupra, Farxiga |
| Veloxis Pharmaceuticals, INC. | $53.19 | 2019 | |
| Abbvie INC. | $49.69 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $43.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $43.02 | 2022-2024 | Capvaxive |
| La Jolla Pharmaceutical Company | $41.78 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $38.95 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $37.08 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $32.02 | 2025 | Auvelity |
| Silk Road Medical, INC. | $30.06 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Insulet Corporation | $29.43 | 2025 | Omnipod |
| Allergan, INC. | $24.77 | 2020 | |
| Xeris Pharmaceuticals, INC. | $23.51 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.65 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.27 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.86 | 2024 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $17.02 | 2024 | Octrode |
| Amarin Pharma, INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmeet Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.